Health Condition 1: F20- Schizophrenia
Conditions
Interventions
Intervention1: Tablet Prucalopride 1 milligram: Tablet Prucalopride 1 miligram per oral once in the morning for a duration of 4 weeks.
Control Intervention1: not applicable: Open label study hence no
Sponsors
St Johns National Academy Of Health Sciences
Eligibility
Inclusion criteria
Inclusion criteria: i) Diagnosed as schizophrenia by DSM 5 criteria ii) Age between 18 to 55 years iii) A minimum of one year of duration of illness iv) Clinically stable with a stable therapeutic dose of antipsychotics for at least 3 months prior to the recruitment v) Participants who can read and write English or Kannada
Exclusion criteria
Exclusion criteria: i) Participants who are acutely symptomatic and are uncooperative for assessments ii) Co morbid with other psychiatric illness including mood disorders and substance use disorders except tobacco iii) Participants already diagnosed with Intellectual Disability Disorder, head injury iv) Participants administered MECT (modified electroconvulsive therapy) in the past 6 months v) Participants with uncorrected sensory impairments vi) Use of Donepezil, Rivastigmine, Memantine, Benzodiazepines vii) Participants already on prucalopride viii) Participants with contraindications to prucalopride like hypersensitivity or diagnosed with intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, gastrointestinal disorders like Ulcerative colitis, Crohn’s disease, Intestinal ulcers, toxic megacolon or megarectum ix) Use of concomitant herbal remedies, alternative medicines x) Women who are pregnant or lactating xi) Current history of suicidal ideation, intention or attempts as assessed during the clinical interview
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Cognitive functioning at the end of 4 weeks and 8 weeks.Timepoint: Assessments will be done at baseline, at the end of 4 weeks and 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 2. Change in Scale for the assessment of Positive symptoms (SAPS) and Scale for the assessment of negative symptoms (SANS) scores at the end of 4 weeks and 8 weeks.Timepoint: Assessment will be done at baseline, at the end of 4 weeks and 8 weeks | — |
Countries
India
Contacts
Public ContactSmitha Tarachandra
K S Hegde Medical Academy
Outcome results
None listed